EMEA-001806-PIP03-18
Key facts
| Invented name |
Kyprolis
|
| Active substance |
carfilzomib
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0171/2019
|
| PIP number |
EMEA-001806-PIP03-18
|
| Pharmaceutical form(s) |
Powder for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Amgen Europe B.V
Tel.: +44 (0)1223 420305 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|